From patient-derived tumor organoids to AI-designed therapies: A closed-loop phenotypic discovery platform

Monday, November 16 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST

This webinar introduces a patient-centred approach to cancer drug discovery that brings together patient-derived tumor organoids, fully automated imaging-based screening with Orbits^® analysis, and artificial intelligence (AI). Prof. Dr. Christophe Deben will explain how starting from real patient tumor models improves the clinical relevance of early drug discovery, and how automation and AI make it possible to develop, test and optimize compounds at scale. He will illustrate the approach with a first-in-class drug candidate discovered entirely through this closed-loop platform, which is further being developed towards the clinic by the spin-off Sightera Biosciences.

Certificate of attendance

If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

Webinar details

Cost: Free to attend

Location: Online

Duration: 60 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.